The Evolving Role of Subcutaneous Therapies in NSCLC
EP. 1: Understanding EGFR Mutations and First-Line Treatment
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine.
EP. 2: Overcoming Resistance Mechanisms and Addressing Unmet Needs
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies.
EP. 3: Impact of Recent Approvals and Novel Mechanisms
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.
EP. 4: CNS Penetration and Efficacy of Emerging Therapies
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.
EP. 5: Managing Adverse Events and Integrating Amivantamab Plus Lazertinib
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.
EP. 6: Sequencing Therapies and Using the Most Effective Options First
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Experts discuss the complexities of treatment sequencing in cancer therapy, emphasizing the importance of using the best therapies upfront for optimal outcomes.
EP. 7: The Value of Subcutaneous Therapy for Patients
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.
EP. 8: FDA Approvals, Patient Selection, and SC Amivantamab
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.
EP. 9: Counseling Patients on IV vs SC Administration
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how shared decision-making empowers patients when choosing between IV and SC administration routes.
EP. 10: Improving Adherence and Transitioning to SC Therapy
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how SC formulations enhance adherence through simpler, patient-friendly treatment delivery.
EP. 11: Impact of SC Formulations on Pharmacy Operations
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how SC formulations streamline pharmacy workflows and optimize oncology practice efficiency.
EP. 12: Barriers to Adoption of SC Therapies
ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.
